Could a common vitamin restore immunotherapy power after antibiotics?
NCT ID NCT07119996
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study looks at whether taking vitamin B3 (a common dietary supplement) can stop antibiotics from weakening the immune system's ability to fight bladder cancer. The trial includes people with a certain type of bladder cancer who have recently taken antibiotics. They will receive a combination of chemotherapy, an immunotherapy drug called tislelizumab, and vitamin B3. The goal is to see if this approach is safe and can help shrink tumors before surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vitamin B3 (nicotinic acid), tislelizumab, gemcitabine, cisplatin
What this could lead to
If it works, this could point toward a way to prevent antibiotics from reducing the effectiveness of immunotherapy in bladder cancer.
What could go wrong
This is a very small, early-phase trial with only 12 participants. The results may not apply to all patients, and the combination could cause side effects from the chemotherapy and immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun-Yatsen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, 510260, China
Contact Phone: •••-•••-•••• Email: •••••@•••••